Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CLEAR HIV Trial: Bempedoic Acid in HIV-associated Atherosclerosis
NCT05488431Phase 2Recruiting
- Start
- Mar 2023
- Primary completion
- Mar 2028
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of bempedoic acid in atherosclerosis, dyslipidemia, cardiovascular disease (CVD). Started Mar 2023; status: recruiting.
02
Drugs
bempedoic acid
03
Conditions
atherosclerosisdyslipidemiacardiovascular disease (CVD)
Beyond the preview
Go deeper on NCT05488431.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05488431.